Margaret T. Kasner, MD

Articles

Practice Pearls for Treatment of Secondary AML in the Community Setting

November 15th 2024

Panelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.

Optimizing AML Care Through Academic-Community Collaboration

November 8th 2024

Panelists discuss how the decision to refer a patient with secondary AML from community practice to an academic or specialized leukemia program should be based on a combination of disease complexity, treatment requirements, and the community center's capabilities, while emphasizing the importance of ongoing collaboration and education to enhance patient care across all settings.

Navigating Intensive Chemotherapy in the Community Setting

November 8th 2024

Panelists discuss how community settings face unique challenges in delivering intensive chemotherapy regimens for secondary AML, including limited resources and expertise, but can implement best practices and leverage potential benefits of community-based care to provide effective treatment.

Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

November 1st 2024

Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.

Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

November 1st 2024

Panelists discuss how identifying candidates for allogeneic transplant in secondary acute myeloid leukemia involves a comprehensive assessment of disease characteristics, patient factors, and timing considerations, while also evaluating fitness for intensive chemotherapy induction using specific criteria to guide treatment decisions.

Patient-Centered Decision-Making in Secondary AML Treatment

October 25th 2024

Panelists discuss how involving patients and caregivers in the treatment decision-making process for secondary acute myeloid leukemia (AML) requires clear communication, education about options, and consideration of individual values and preferences to ensure informed and shared decision-making.

The Role of Molecular and Cytogenetic Testing in Secondary AML

October 25th 2024

Panelists discuss how comprehensive molecular and cytogenetic testing at diagnosis is crucial for accurate risk stratification, treatment selection, and prognostication in secondary acute myeloid leukemia (AML), while acknowledging the challenges of obtaining timely results, especially in community settings.

Treatment Goals in Secondary AML

October 18th 2024

Panelists discuss how secondary acute myeloid leukemia (AML) generally carries a poorer prognosis compared to de novo AML, necessitating careful consideration of treatment goals and open communication with patients about their outlook.

Implementing Updates to AML Classification Guidelines

October 18th 2024

Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.

Optimizing Treatment Selection for Patients with FLT3-ITD AML

July 24th 2023

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

July 17th 2023

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

July 17th 2023

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

June 26th 2023

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

June 26th 2023

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Future Directions in the Management of Acute Myeloid Leukemia

March 21st 2023

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.

Emerging Treatment Strategies in Acute Myeloid Leukemia

March 21st 2023

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Sequencing Therapies in Patients With Relapsed/Refractory AML

March 14th 2023

Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.

A Potential Role for IDH-1 Inhibitor Olutasidenib in Relapsed/Refractory AML?

March 14th 2023

Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.

Treatment Strategies in Patients With Relapsed/Refractory AML

March 7th 2023

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Role of Stem Cell Transplant in Acute Myeloid Leukemia

March 7th 2023

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.